Study:
Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma
Rationale:
Drugs used in chemotherapy such as methotrexate and temozolomide use different
ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies
such as rituximab can locate cancer cells and either kill them or deliver cancer-killing
substances to them without harming normal cells. Radiation therapy uses high-energy x-rays
to damage cancer cells. Combining methotrexate, temozolomide, and rituximab with radiation
therapy may kill more cancer cells.
Purpose:
This phase I/II trial is studying the side effects and best dose of temozolomide
when given together with methotrexate and rituximab followed by radiation therapy and to see
how well they work in treating patients with primary central nervous system lymphoma.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Brain and Central Nervous System Tumors
Lymphoma |
Biological: rituximab
Drug: methotrexate
Drug: temozolomide
Radiation: radiation therapy |
Phase 1/Phase 2 |
Verified by
Radiation Therapy Oncology Group
July, 2012
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00068250
Study Type: Interventional
Study Design: Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Jon Glass, MD., Study Chair